Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

77.75 +0.46 (+0.60%)
Streaming Delayed Price Updated: 11:22 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,840
Open 77.47
Bid (Size) 77.58 (400)
Ask (Size) 77.93 (200)
Prev. Close 77.29
Today's Range 77.39 - 78.74
52wk Range 49.00 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Corcept Therapeutics Inc (NASDAQ:CORT) Presents a Strong Growth and Technical Breakout Case ↗
Corcept Therapeutics (CORT) combines strong fundamentals, including robust revenue growth and a healthy balance sheet, with a positive technical breakout setup. 
Via Chartmill
News headline image
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. 
Via StockStory
Topics Economy

Performance

YTD
+55.6%
+55.6%
1 Month
+7.2%
+7.2%
3 Month
+13.0%
+13.0%
6 Month
+1.2%
+1.2%
1 Year
+31.7%
+31.7%

More News

Read More
News headline image
CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Case Study in Affordable Growth Investing ↗
Via Chartmill
News headline image
1 Growth Stock with Explosive Upside and 2 We Brush Off
Via StockStory
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
The 5 Most Interesting Analyst Questions From Corcept’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Peering Into Corcept Therapeutics Inc's Recent Short Interest ↗
Via Benzinga
News headline image
CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook
Via StockStory
News headline image
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings
Via StockStory
News headline image
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Earnings: What To Look For From CORT
Via StockStory
Topics Artificial Intelligence
News headline image
3 Healthcare Stocks We Steer Clear Of
Via StockStory
Topics Stocks
News headline image
3 Cash-Producing Stocks with Open Questions
Via StockStory
News headline image
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock ↗
Via Benzinga
News headline image
Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk ↗
Via Stocktwits
News headline image
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm
Via StockStory
News headline image
Corcept (CORT) Shares Skyrocket, What You Need To Know
Via StockStory
News headline image
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 High-Flying Stocks We Approach with Caution
Via StockStory
News headline image
3 Profitable Stocks That Concern Us
Via StockStory

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 77.75
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 11/24/25 11:22 AM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 9.01B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.